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Maternal vitamin B12 deﬁciency during pregnancy is an independent risk factor for neural tube defects and other neurological
problems in infants. We determined the vitamin B12 status of 143 pregnant women in Nigeria representing all trimesters who
presented to an antenatal clinic in Jos, Nigeria, using holotranscobalamin II levels (holoTCII), which is a measure of the vitamin
B12 that is available for uptake into tissues. The holoTCII concentration ranged from 13 to 128pmol/L. Using a cutoﬀ of
40pmol/L,36%ofthewomenwereclassiﬁedasvitaminB12-deﬁcient.HoloTCIIconcentrationscorrelatednegativelywithplasma
homocysteinelevels(r = −0.24,P = 0.003)andpositivelywithredbloodcellfolateconcentrations(r =0.28,P<0.001).Thesedata
underscore the importance of supplementing pregnant women in Nigeria with vitamin B12 in order to ensure adequate vitamin
B12 status and decrease the risk for neural tube defects.
1.Introduction
Adequate vitamin B12 status during pregnancy is critical
since maternal vitamin B12 deﬁciency is associated with inc-
reased risk for several adverse pregnancy outcomes for both
mother and fetus. These risks include neural tube defects
[1–4], intrauterine growth retardation [5], preeclampsia [6]
and early miscarriage [7, 8]. Furthermore, fetal vitamin B12
accumulation during gestation is the major determinant of
theB12statusofthenewbornandofstoresininfancy[9–12].
Even though a mother may not exhibit any hematological
or neurological symptoms of B12 deﬁciency, an exclusively
breast-fed infant born to a mother who is deﬁcient in
vitamin B12 can develop symptoms within several months
following delivery [13, 14]. These include failure-to-thrive,
megaloblastic anemia, and neurological symptoms [15].
Vitamin B12 is present only in foods of animal origin
such as meat, dairy products, and ﬁsh [16, 17]. Thus, indivi-
duals adhering to a vegetarian diet or residing in parts of
the developing world where consumption of foods from
animal sources is limited because of cost or availability will
be predisposed to vitamin B12 deﬁciency [18]. There is
increasingevidencethattheglobalprevalenceofvitaminB12
deﬁciency, particularly in the developing parts of the world,
is underappreciated [11, 19–22].
In a previous study of 146 pregnant women in Nigeria
[23], we found that 9% of them had a serum vitamin B12
concentration below 148pmol/L, which is the cutoﬀ for
B12 deﬁciency [24]. In a subsequent study of 98 pregnant
Nigerian women [25], we documented that 12% of the
subjects had vitamin B12 levels in the deﬁciency range and
about one in ﬁve had an elevated serum methylmalonic
(MMA) concentration, which is a speciﬁc metabolic marker
of vitamin B12 deﬁciency [26]. Applying the criteria pro-
posed by Carmel and associates [24] of a combined low
vitamin B12 level (<148pmol/L) and a MMA concentration2 ISRN Obstetrics and Gynecology
greaterthan270μmol/L,8%ofthewomeninthatstudywere
determined to have subclinical vitamin B12 deﬁciency.
Measurement of the total vitamin B12 concentration in
plasma is the usual method for assessing vitamin B12 status.
However, neurological and hematological symptoms of
deﬁciency can occur in individuals with plasma vitamin B12
concentrations in the low-normal range [27]. Conversely,
some individuals with low vitamin B12 concentrations
remain symptom-free. Moreover, the plasma vitamin B12
concentrationisnotareliableindicatorofvitaminB12status
in pregnancy since there is a gradual, physiologically normal
decline in the plasma concentration of vitamin B12 during
anuncomplicatedpregnancy[28,29].Thisdeclineisthought
to be due to hemodilution, hormonal changes, alterations in
the concentration of vitamin B12 binding proteins, or active
transport of vitamin B12 across the placenta [30].
In the circulation, vitamin B12 is bound by two diﬀerent
transport proteins: approximately 70%–80% is carried by
haptocorrin while the remainder is bound to transcobalamin
II (holotranscobalamin, holoTC) [31]. Only that vitamin
B12 which is bound to holoTC is available to tissues through
uptake mediated by receptors for the B12/transcobalamin
complex [32]. The function of circulating vitamin B12
bound to haptocorrin is not known, but may represent that
portion of vitamin B12 which is being returned to the liver
for excretion in the bile or physiologically inert metabolites
of vitamin B12.
Holotranscobalamin is a more sensitive indicator of vita-
min B12 status than the total serum vitamin B12 level or the
serum concentration of MMA and homocysteine (Hcys),
both of which are elevated in vitamin B12 deﬁciency [33–
35] .M o r e o v e r ,i na ni n v e s t i g a t i o no ft h ec i r c a d i a nv a r i a t i o n
of holoTC, Hvas and coworkers [36] found no signiﬁcant
changes in serum holoTC concentrations in healthy vitamin
B12-replete subjects consuming a standard diet. They con-
cluded, therefore, that holoTC is not an indicator of recent
dietary intake but rather a marker of long-term vitamin
B12 status. In addition, in a longitudinal study of healthy
pregnant women from 18 weeks gestation up to the time of
delivery, Morkbak and coworkers [37] observed that altho-
ugh serum vitamin B12 levels decreased over the course of
the pregnancy, holoTC levels remained constant in women
with an adequate intake of vitamin B12.
In light of the importance of adequate vitamin B12 status
to the well-being of the fetus during pregnancy, the present
study was designed to use the measurement of plasma
holoTC to assess the vitamin B12 status of pregnant women
attending at an antenatal clinic in Nigeria for the ﬁrst time in
their current pregnancy.
2.SubjectsandMethods
2.1. Subjects. This study was conducted at the Antenatal Cli-
nicoftheJosUniversityTeachingHospital(JUTH),atertiary
care facility in Jos, Nigeria. Healthy women representing all
trimesterswhopresentedattheclinicfortheﬁrsttimeduring
their current pregnancy were invited to enroll in the study.
Subjects were enrolled after the purpose and requirements of
the study had been explained to them in English or Hausa
by the attending physician in the clinic. Informed written
consent was obtained from each participant. This study was
approved by the Ethics Review Committee of JUTH and by
the Human Research Review Committee of the University
of New Mexico Health Sciences Center, Albuquerque, New
Mexico.
Self-reported information regarding subjects was cap-
tured by interview and included age, gravidity, parity,
occupation, educational background, ethnic group, previous
clinic visits, vitamin supplementation, and fever. Gestational
age was estimated based on the date of the last menstrual
cycle. At the completion of the interview, subjects were asked
to provide a blood sample for biochemical analyses and
malaria testing. Since infection with intestinal parasites is
known to aﬀect vitamin B12 status [38, 39], each subject was
given a container and asked to return with a stool sample
the next day for the analysis of the presence of intestinal
parasites.
2.2. Anthropometric Measurements. The weight of each sub-
ject was measured using a portable scale accurate to 0.5kg
thatwasstandardizedeachdayusingaknownweight.Height
was measured using a portable stadiometer readable to
0.25cm (Creative Health Products, Plymouth, Mich, USA).
2.3. Malaria Screening. Infection with malaria was determi-
nedusingtheCareStart MalariapLDHrapidtest(AccessBio,
Inc., NJ, USA). The test, which is designed for the diﬀerential
diagnosis of Plasmodium falciparum and other Plasmodium
species, has a sensitivity of 96% and speciﬁcity of 98.5%
when compared to microscopic examination of whole blood.
2.4. Intestinal Parasite Screening. Stool samples were prese-
rvedin10%(v/v)formol-salineandlaterscreenedforintesti-
nal parasites using a formol-ether concentration method
[40]. Brieﬂy, approximately 2g of stool sample were placed
in a 15mL conical centrifuge tube and brought to 7mL with
10%(v/v)formol-saline.Ether(3mL)wasthenaddedtogive
a total volume of 10mL. The sample was vortexed and then
centrifuged at 1200×g for 5min in a clinical centrifuge. The
supernatant was decanted, and one drop of the pellet was
added to a glass slide and stained with Lugol’s iodine and
then examined under a light microscope for the presence of
parasites [41].
2.5.BiochemicalMeasurements. Abloodsamplewasobtained
from each subject by venipuncture and collected in a hepa-
rinized vacutainer tube. The packed cell volume (PCV) was
determinedforeachsubjectbycentrifugationofanaliquotof
whole blood in a microhaematocrit tube in a READACRIT
centrifuge (Clay Adams, Parsippany, NJ, USA) for 5min.
The remaining sample was divided into two portions: 1mL
whole blood to be used for the determination of hemoglobin
and red blood cell folate was transferred to a cryovial tube
and stored at −70◦C; the remainder of the blood sample
was centrifuged at 1200×g to separate plasma and cells and
the plasma fraction was stored at −70◦C. The samples were
transported in the frozen state to Albuquerque, NM for
biochemical analyses.ISRN Obstetrics and Gynecology 3
Hemoglobin concentration was determined by colori-
metric analysis of lysed whole blood using the Hemoglobin
B test kit (Wako Chemicals, Richmond, VA, USA). Total
vitamin B12 was measured using the IMMULITE 2500
Vitamin B12 solid phase, two-site chemiluminescent enzyme
immunoassay in the IMMULITE 2500 analyzer (Diagnostic
Products Corporation, Los Angeles, Calif, USA). The test
is sensitive to 92pmol/L and has a coeﬃcient of variation
(CV) less than 10%. Vitamin B12 bound to transcobalamin
II (holoTC) was determined using the AxSYM Active B12
microparticle enzyme immunoassay (Abbott Diagnostics,
AxSYM, Abbott Park, Ill, USA). The test is sensitive to
1pmol/L with a coeﬃcient of variation of less than 10%.
Plasmafolateandwholebloodfolateconcentrationswere
determined using the IMMULITE 2500 Folic Acid Assay for
the IMMULITE 2500 analyzer (Diagnostic Products Corpo-
ration, Los Angeles, Calif, USA). The red blood cell folate
concentration was calculated using the whole blood folate
concentration, hematocrit and plasma folate concentration.
Plasma homocysteine (Hcys) was measured using the
IMMULITE 2000 Homocysteine Competitive Immunoassay.
Plasma ferritin was measured using the VITROS Ferritin
two-step immunometric assay on the VITROS Eci Immu-
nodiagnostic System (Ortho-Clinical Diagnostics, Inc., Roc-
hester, NY, USA).
2.6. Statistical Analysis. Descriptive statistics, group com-
parisons, and correlation analyses were performed using
the Number Cruncher Statistical Software (NCSS, Kaysville,
Utah, 2006). Variables with a normal distribution are
presented as the mean ± 1 standard deviation. Variables that
were not normally distributed are presented as the median
(minimum-maximum). Comparisons between trimesters
were performed using one-way ANOVA. The vitamin B12
concentrations for the women with intestinal parasites were
compared to those without intestinal parasites using the
t-test. Correlations were determined using the Spearman
correlation coeﬃcient. A P value of ≤0.05 was considered
statistically signiﬁcant.
3. Results
3.1. Subjects. A total of 143 women were enrolled in the
s t u d y .T h ew o m e nr a n g e di na g ef r o m1 8t o5 3y e a r s
(Table 1). The majority of the subjects were Hausa (n = 35),
followed by Berom (n = 18), Fulani (n = 12), Igbo (n = 9),
and Yoruba (n = 7). The remainder (n = 61) reported other
ethnic designations. Forty-three of the women reported
having less than six years of schooling, 50 had greater than
six years of school, and 48 had attended university. The
educational background of two women was not available.
Housewives accounted for the highest number of subjects
(n = 38), followed by tailors (n = 31), students (n = 17),
traders (n = 16), professionals (n = 12), teachers (n = 10),
clerical workers (n = 10), and other occupations (n = 8).
The majority of the women (n = 88, 61%) were in the
second trimester; 30 (21%) were in the ﬁrst trimester and 25
(17%) in the third trimester. Supplements were used by 11
women: 10 were taking iron and folate supplements, whereas
only1subjectreportedtakingafolatesupplementonly.Eight
of the 11 women who were taking supplements had previous
pregnancies. The mean blood pressure for all of the subjects
was in the normal range (Table 1), except for one woman
who had an elevated blood pressure (>140/>90mmHg); she
was evaluated and treated by a physician.
3.2. Malaria Screening. Six of the subjects tested positive for
malaria; however, only one woman reported experiencing
fever. All positive results were due to infection with P.
falciparum, and all women who tested positive for malaria
were given medication.
3.3. Stool Screening. Stool samples were obtained from 121
of the 143 subjects. At least one species of intestinal parasite
was found in the stool samples of 29 of the 121 subjects.
Sixteen of the women tested positive for more than one
parasite. The most common parasite found was Entamoeba
histolytica (n = 18), followed by Endolimax nana (n = 12),
Entamoeba coli (n = 12), Dicrocoelium dendriticum (n = 3),
hookworm (n = 2), and Giardia lamblia (n = 2).
3.4. Biochemical Analyses. The results of the biochemical
analyses are summarized in Table 2. The mean hemoglobin
concentration for the 143 subjects was 108g/L. According
to the Centers for Disease Control and Prevention [42], a
hemoglobin concentration less than 110g/L in the ﬁrst and
third trimesters and less than 105g/L in the second trimester
is indicative of anemia. According to these criteria, 56 (36%)
of the subjects were anemic: 5 of the 30 subjects in the
ﬁrst trimester, 33 of the 88 women in the second trimester,
and 9 of 25 women in the third trimester. None of the
subjects in the anemic category reported taking an iron or
folic acid supplement. Despite the high number of subjects
in the anemic range, only 16 (11%) of them had a ferritin
concentration below 10ng/mL [43].
Five (4%) of the total subjects had a serum folate
concentration less than 7.7nmol/L, whereas 117 (81%) had
a red blood cell folate concentration below 317nmo/L.
Although serum folate concentrations did not correlate
with plasma Hcys levels, there was a signiﬁcant negative
correlation between plasma Hcys concentrations and red
blood cell folate concentrations (P = 0.015, r =− 0.20).
Thirty-six (25%) of the pregnant women had a plasma
totalvitaminB12concentrationbelow148pmol/L,thecutoﬀ
for vitamin B12 deﬁciency: 27% of women in the ﬁrst
trimester, 23% in the second trimester, and 32% in the third
trimester. The plasma vitamin B12 concentrations of the
subjects in the second and third trimesters were signiﬁcantly
lower than the values of subjects in the ﬁrst trimester (P =
0.02, Table 2). The plasma vitamin B12 concentration was
positively correlated with red blood cell folate level (Figure 1,
r = 0.28, P<0.001) and negatively correlated serum Hcys
concentration (r =− 0.24, P = 0.003).
TheholoTCconcentrationsforthepregnantwomenran-
ged from 13 to 128pmol/L, with a mean value of 53pmol/L.
Using a holoTC cut-oﬀ value of 40pmol/L determined for
the AxSYM Active B12 immunoassay [44], 52 (36%) sub-
jects were vitamin B12 deﬁcient: 30% of the women in the4 ISRN Obstetrics and Gynecology
Table 1: Summary of the anthropometric characteristics of pregnant women attending an antenatal clinic in Jos, Nigeria, for the ﬁrst time
in their current pregnancy.
Total Trimester
123
(n = 143) (n = 30) (n = 88) (n = 25)
Parameter Mean ± S.D.
Age (yrs) 28.0 ± 6.1 26.9 ± 5.9 28.1 ± 5.9 29.1 ± 6.7
Weight (kg) 63.3 ± 13.2 61.4 ± 12.8 63.1 ± 13.1 66.5 ± 14.2
Height (cm) 159.8 ± 5.9 160.2 ± 5.1 160.1 ± 6.1 157.9 ± 5.8
Gravida (n) 3 (1–10)∗ 3 (1–7) 2 (1–10) 5 (1–9)
Blood pressure (mmHg)
Systolic 109 ± 15 110 ± 13 111 ± 16 105 ± 15
Diastolic 64 ± 10 66 ± 96 4 ± 11 60 ± 10
∗Median (minimum-maximum).
Table 2: Summary of the biochemical analyses for pregnant women attending an antenatal clinic in Jos, Nigeria, for the ﬁrst time in their
current pregnancy.
Total Trimester
123
(n = 143) (n = 30) (n = 88) (n = 25)
Mean ± SD
Hemoglobin (g/L) 108 ± 13 114 ± 11a 107 ± 13 106 ± 14
Hematocrit (%) 37 ± 43 9 ± 4b 36 ± 43 6 ± 4
Vitamin B12 (pmol/L) 199 (111–738)∗ 346 (111–738)c 197 (111–738) 164 (111–738)
Holotranscobalamin (pmol/L) 53 ± 28 52 (14–123) 52 (15–128) 45 (13–128)
Serum folate (nmol/L) 20 ± 12 27 ± 12e 19 ± 12 14 ± 5
Red blood cell folate (nmol/L) 240 ± 110 271 ± 132 241 ± 106 199 ± 86
Homocysteine (μmol/L) 7.7 ± 2.4 7.7 ± 2.1 7.7 ± 2.4 7.6 ± 2.9
Ferritin (ng/mL) 27.5 (4.8–285) 55.6 (12–218)d 24.4 (4.8–285) 17.6 (6.8–160)
∗Median (minimum-maximum); trimester 1 diﬀerent from trimesters 2 and 3, aP = 0.016, bP ≤ 0.001, cP = 0.015, dP<0.001; esigniﬁcant diﬀerence
between all trimesters, P ≤ 0.001.
ﬁrst trimester, 38% in the second trimester, and 40% in the
thir dtrimest er .TheholoT Clev elsw er enotdiﬀerentbetween
trimesters.Twenty-eightofthe56womenwhowereclassiﬁed
as anemic on the basis of hemoglobin concentration had a
holoTC level below the 40pmol/L cutoﬀ. Holotranscobal-
amin II concentration was negatively correlated with serum
Hcys level (r =− 0.24, P = 0.003, Figure 1), but positively
correlatedwithredbloodcellfolateconcentration(r = 0.28,
P<0.001; Figure 2). Eight of the 29 women with intestinal
parasites had a plasma transcobalamin concentration in the
deﬁcient range.
4. Discussion
Inadequate maternal vitamin B12 status during pregnancy
places the fetus at risk for a neural tube defect before birth,
and for anemia and neurological disorders following birth.
Using the plasma holoTC concentration as an indicator of
physiologically available vitamin B12, in the present study
we found that 36% of pregnant Nigerian women presenting
at an antenatal clinic for the ﬁrst time in their current
pregnancy had a plasma holoTC concentration indicative of
vitamin B12 deﬁciency.
Vitamin B12 accumulation in utero is the major determi-
nant of vitamin B12 status in the newborn and throughout
infancy (9–12). Vitamin B12 is actively transported across
the placenta [45], and strong correlations between maternal
a n dn e wb o r nvi t a m i nB 1 2s t a t u sh a v eb e e nd o c u m e n t e d[ 46,
47]. Giugliani and associates [45] estimated that an infant
born to a vitamin B12-replete mother will have vitamin B12
stores in the 25 to 30μg range. Based on an average breast
milk concentration of 0.42μg/L in B12-replete mothers [48],
an infant consuming 780mL breast milk would obtain
approximately 0.3μg/day of vitamin B12 from milk. This
amount is close to the recommended adequate intake (AI)
of 0.4μg/day for infants up to 6 months of age [49]. The
remaining vitamin B12 must be supplied by the hepatic
vitamin B12 stores of the infant. Assuming a withdrawal
of 0.10 to 0.20μg/day from hepatic stores, an infant would
normally have a 4- to 6-month reserve of vitamin B12.
However, the vitamin B12 content of milk from women who
have inadequate vitamin B12 intake will be lower, in theISRN Obstetrics and Gynecology 5
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Figure 1: The relation between serum holotranscobalamin II
concentrations and serum homocysteine concentrations; r =
−0.24, P = 0.003.
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Figure 2: The relation between serum holotranscobalamin II
concentrations and red blood cell folate concentrations.; r = 0.28;
P<0.001.
rangeof0.13to0.36μg/L[50,51],andthevitaminB12stores
of an infant born to such a mother would be expected to be
correspondingly low.
Although adults can tolerate inadequate intake of vita-
min B12 for a long period of time, infants on the other hand
develop symptoms of B12 deﬁciency much more rapidly if
they have inadequate liver stores of the vitamin. Symptoms
of vitamin B12 deﬁciency in infants include failure-to-thrive,
irritability, apathy, anorexia, refusal of solid foods, mega-
loblastic anemia, and developmental delays [15]. Although
treatment with vitamin B12 can reverse these symptoms,
infants treated for vitamin B12 deﬁciency often suﬀer long-
term cognitive and developmental retardation [52] depend-
ing on the severity and duration of the vitamin deﬁciency.
The basis for the neurological eﬀects of vitamin B12
deﬁciency in infants has not been established, but several
mechanisms have been proposed [53]. These include delayed
myelination or demyelination of nerves, an alteration in the
S-adenosylmethionine-S-adenosylhomocysteineratio(SAM/
SAH), and an imbalance in neurotrophic and neurotoxic cy-
tokines. Guerra-Shinohara and coworkers [54] reported that
cord blood from newborns of mothers with low levels of
serum vitamin B12 had below-normal concentrations of
SAM and elevated concentrations of SAH, and concluded
that methylation reactions were impaired in these newborns.
Therefore, the accumulation of odd-chain fatty acids and
impaired methylation processes could contribute to the syn-
thesis of unstable myelin and subsequent demyelination of
nerves.
Folic acid fortiﬁcation of food in several countries,
including the US and Canada, has been proven to greatly
reduce, but not eliminate entirely, the incidence of NTDs
[55]. Other factors, including vitamin B12, have been shown
to be independent risk factors for NTDs [1–4]. The reported
association between maternal vitamin B12 insuﬃciency and
risk for neural tube defects is of special concern for pregnant
women in sub-Saharan Africa because of the high incidence
of NTDs. Although there are few reports documenting the
incidence of neural tube defects in Nigeria and other regions
of sub-Saharan Africa, a three-year prospective study in Jos,
Nigeria recorded an incidence of 7/1000 deliveries [56]. In
a more recent three-year retrospective study in southern
Nigeria, Ugwu and coworkers [57] found the incidence of
NTDs to be 0.95/1000 births. In neighboring Cameroon, an
NTD incidence of 1.99/1000 births was reported over a 10-
year period [58]. In contrast, the incidence of neural tube
defects for the Group 8 (G8) countries has been reported to
be much lower at 0.3 to 0.4/1000 births [59].
Red-cell folate is regarded as a better indication of tissue
folate content than the serum folate level. The correla-
tion between holoTC and red-cell folate concentration we
observed in the present study underscores the importance
of vitamin B12 status in the maintenance of tissue folate
[60].5-Methyltetrahydrofolymonoglutamateistheprinciple
form of folate in blood and the form taken by tissues. Once
inside the cell, the monoglutamate form must be elongated
to the polyglutamate form in order to be retained by the
cell. However, 5-methyltetrahydrofoalte is a poor substrate
for polyglutamate synthase, the enzyme that catalyzes this
polymerization reaction, and must ﬁrst be converted to
tetrahydrofolate in the vitamin B12-dependent reaction
catalyzed by methionine synthase. Therefore, in vitamin B12
deﬁciency, the concentration of tissue folate polyglutamate
is commonly decreased while the 5-methyltetrahydrofolate
form in serum is elevated. In the present study, 45/117 (38%)
of the subjects with low red blood cell folate had a plasma
holoTCconcentrationbelow40pmol/L,whereasonly5(4%)
of the subjects had a plasma folate concentration below the
lower limit of normal (7.7nmol/L).
One of the limitations of the present study was that
dietary intake of vitamin B12 was not assessed. A previous
study of the diets of individuals residing in the same locality
as the present study found that the dietary intake of vitamin
B12 by non-pregnant women was 2.9 ± 1.7μg/day [61]. The
current Adequate Intake (AI) for pregnant women set by the
Institute of Medicine in the US is 2.6μg/day [62]. However,
in a recent study of the relation between dietary vitamin B12
intake and B12-related biomarkers in a healthy population6 ISRN Obstetrics and Gynecology
between 18–50 years of age, Bor and coworkers [63]f o u n d
that all of the biomarkers used, including plasma vitamin
B12, holoTC, MMA, and Hcys, leveled oﬀ at a daily intake
between 4.2 and 7.0μg/day. They suggested that the current
AI for vitamin B12 may be inadequate even for a healthy
population.InastudyofpostmenopausalDanishwomen,an
intake of 6μg/day was determined to normalize all vitamin
B12-related parameters [64].
The dietary source of vitamin B12 strongly inﬂuences
its bioavailability. In a study of the sources of vitamin B12
and their association with plasma vitamin B12 levels, Vogiat-
zoglou and coworkers determined that the bioavailability of
vitamin B12 was greater from dairy products and ﬁsh than
from meat [65]. In the dietary study we conducted in Jos,
Nigeria [63], only 10% of the protein in the diets of the
women was derived from eggs and milk, with 25% of protein
coming from meat.
Women attending the antenatal clinics in this region are
routinely given iron and folate supplements when they
register at the clinics in order to prevent anemia, but are
not prescribed multivitamins or vitamin B12 supplements.
The present study provides reason to suggest that pregnant
women attending antenatal clinics in Nigeria would beneﬁt
from vitamin B12 supplementation. This practice would
support the Millenium Development Goals [66]t op r o m o t e
the health of mothers and infants in developing countries.
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